Establishing a second major collaboration, this time in the fields of cancer and tissue repair, Curis Inc. and Genentech Inc. joined forces to discover and develop small-molecule modulators of an undisclosed pathway. (BioWorld Today)
Less than a year after withdrawing a proposed initial public offering, TolerRx Inc. dipped into the private markets, raising $31 million in a Series D round. (BioWorld Today)
